GO
Loading...

GlaxoSmithKline PLC

More

  • LONDON/ NEW YORK, Sept 12- As electronic cigarettes flew off shelves on both sides of the Atlantic in recent years, investors flocked to a business some hope will be the future for tobacco.

  • The worst-ever Ebola outbreak, which has already killed at least 2,296 people in West Africa, has triggered a scramble to develop the first drug or vaccine for a deadly disease that was discovered nearly 40 years ago in the forests of central Africa.

  • JOHANNESBURG, Sept 10- Aspen Pharmacare is to sell the rights to market a blood clot drug in the United States to rival Mylan Inc for up to $300 million, it said on Wednesday, a move that would help Africa's top generic drugmaker pay down debt.

  • Early movers: HD, AAPL, MCD, DHI, RL, T, BA & more Tuesday, 9 Sep 2014 | 7:58 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • SHANGHAI/ WASHINGTON, Sept 9- A U.S. anti-bribery probe into GlaxoSmithKline Plc touched on the firm's Chinese consumer healthcare business in 2012, internal documents show, suggesting the drugmaker's compliance problems in China could go wider than previously revealed.

  • Midday movers: Boeing, Ford Motor, Yahoo & more Monday, 8 Sep 2014 | 1:24 PM ET

    Some of Monday's midday movers:

  • Sept 4- NewLink Genetics Corp said the U.S. Food and Drug Administration allowed the company to start testing an experimental Ebola vaccine in humans. The move follows a decision to begin initial human testing of a GlaxoSmithKline vaccine this month and an approval to fast track tests of a Johnson& Johnson vaccine.

  • Sept 3- Chimerix Inc said its lead experimental drug showed promise against the deadly Ebola virus in laboratory testing at the U.S. Centers for Disease Control and Prevention and the National Institutes of Health.

  • Sept 2- The U.S. Department of Health and Human Services said on Tuesday a federal contract worth up to $42.3 million would help accelerate testing of an experimental Ebola virus treatment that is being developed by privately held Mapp Biopharmaceutical Inc..

  • PRESS DIGEST-Sunday British Business - AUG 31 Sunday, 31 Aug 2014 | 9:28 AM ET

    LONDON, Aug 31- British newspapers reported the following business stories on Sunday. GlaxoSmithKline is facing a shareholder revolt over plans to shake up its board, with leading investors calling for the speedy departure of Chairman Christopher Gent.

  • The success is therefore a "monumental achievement," virologist Thomas Geisbert of the University of Texas Medical Branch wrote in a commentary on the paper, published online in Nature.

  • Aug 29- BioCryst Pharmaceuticals Inc said it expects to initiate a study within weeks to test its antiviral in primates for use against Ebola infections. This $2.4 million National Institute of Allergy and Infectious Diseases funding is in addition to the $22 million contract awarded to BioCryst by the agency last September.

  • Ebola outbreak could infect 20,000, WHO says Thursday, 28 Aug 2014 | 10:46 PM ET
    In this handout from the Center for Disease Control, a colorized transmission electron micrograph (TEM) of a Ebola virus virion is seen.

    The Ebola epidemic in West Africa could infect 20,000 people, warning that an international effort costing almost half a billion dollars is needed.

  • CHICAGO, Aug 28- Genetic studies of some of the earliest Ebola cases in Sierra Leone reveal more than 300 genetic changes in the virus as it leapt from person to person, changes that could blunt the effectiveness of diagnostic tests and experimental treatments now in development, researchers said on Thursday.

  • GENEVA/ LAGOS Aug 28- The Ebola epidemic in West Africa could infect more than 20,000 people, the U.N. health agency said on Thursday, warning that an international effort costing almost half a billion dollars is needed to overcome the outbreak.

  • Human trials of Ebola vaccine to start next week Thursday, 28 Aug 2014 | 8:09 AM ET
    Medicins Sans Frontieres health workers at an isolation camp in Liberia during the visit of the UN Ebola systems coordinator, Aug. 23, 2014.

    The trials will start at the NIH in Maryland. A vaccine is "the first step in a long process" to control Ebola, Dr. Anthony Fauci says. NBC reports.

  • Early movers: ANF, DG, GS, JPM, C, GSK, WSM & more Thursday, 28 Aug 2014 | 7:58 AM ET

    Some of the names on the move ahead of the open.

  • LONDON/ NEW YORK, Aug 28- An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build a stockpile of up to 10,000 doses for emergency deployment, if results are good.

  • WINNIPEG, Manitoba, Aug 25- Four monkeys survived the Ebola virus after being injected with a vaccine that included Immunovaccine Inc's technology, the tiny Canadian company said on Monday, and the announcement sent its stock soaring.

  • BofA set to face the music with $17B settlement Thursday, 21 Aug 2014 | 8:32 AM ET
    A man uses an ATM at a Bank of America branch on April 16, 2014 in New York City.

    The long-anticipated settlement is expected to consist of a penalty of $9.6 billion and a package of consumer-relief measures valued at $7 billion.